Applied DNA Sciences (NASDAQ:APDN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Applied DNA Sciences (NASDAQ:APDN) in a research report sent to investors on Saturday. The firm issued a sell rating on the technology company’s stock.

Separately, HC Wainwright lowered their price objective on shares of Applied DNA Sciences from $7.00 to $1.50 and set a buy rating for the company in a research note on Monday, June 10th.

Applied DNA Sciences Price Performance

Shares of APDN opened at $0.41 on Friday. The company has a market cap of $400,232.00, a price-to-earnings ratio of -0.02 and a beta of 0.08. Applied DNA Sciences has a twelve month low of $0.37 and a twelve month high of $37.20. The company has a 50 day moving average of $2.06 and a two-hundred day moving average of $7.87.

Applied DNA Sciences (NASDAQ:APDN) last posted its quarterly earnings data on Friday, May 10th. The technology company reported ($5.31) EPS for the quarter, missing the consensus estimate of ($4.60) by ($0.71). Applied DNA Sciences had a negative return on equity of 306.32% and a negative net margin of 222.33%. The company had revenue of $0.93 million for the quarter, compared to analyst estimates of $0.90 million. On average, sell-side analysts expect that Applied DNA Sciences will post -2.95 EPS for the current year.

Institutional Investors Weigh In On Applied DNA Sciences

A hedge fund recently bought a new stake in Applied DNA Sciences stock. Silverberg Bernstein Capital Management LLC bought a new stake in shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 98,301 shares of the technology company’s stock, valued at approximately $61,000. Silverberg Bernstein Capital Management LLC owned 0.72% of Applied DNA Sciences at the end of the most recent reporting period. Institutional investors own 22.22% of the company’s stock.

About Applied DNA Sciences

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.